Merck KGaA (CHIX:MRKD) EPS (Basic): €5.83 (TTM As of Mar. 2026)


CHIX:MRKD Merck KGaA CHIX:MRKD
83 GF Score
Price €128.75
GF Value €140.71
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Merck KGaA EPS (Basic)?

Merck KGaA CHIX:MRKD 83 EPS (Basic) is €5.83 as of Mar. 2026. GuruFocus rates CHIX:MRKD with a GF Score™ of 83/100 and a GF Value™ of €140.71 (Fairly Valued). The stock has 9 warning signs investors should review.

Merck KGaA's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €1.52. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €5.83.

Merck KGaA's EPS (Diluted) for the three months ended in Mar. 2026 was €1.52. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €5.83.

Merck KGaA's EPS without NRI for the three months ended in Mar. 2026 was €1.53. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 6.32.

During the past 12 months, Merck KGaA's average EPS without NRIGrowth Rate was -12.60% per year. During the past 3 years, the average EPS without NRI Growth Rate was -7.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 5.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 9.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Merck KGaA's highest 3-Year average EPS without NRI Growth Rate was 48.90% per year. The lowest was -16.70% per year. And the median was 3.00% per year.

Merck KGaA  (CHIX:MRKd) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Merck KGaA EPS (Basic) Related Terms

Merck KGaA EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Merck KGaA's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA EPS (Basic) Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.03 7.65 6.49 6.39 6.00

Merck KGaA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.69 1.50 2.07 0.74 1.52
CHIX:MRKD
83GF Score
Merck KGaA CHIX:MRKD
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck KGaA EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Merck KGaA's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(2608-0)/434.778
=6.00

Merck KGaA's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(659-0)/433.553
=1.52

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €5.83 mean?
Merck KGaA (CHIX:MRKD) has a EPS (Basic) of €5.83 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Merck KGaA and its competitors.
Is Merck KGaA's EPS (Basic) too high?
Merck KGaA's current EPS (Basic) is €5.83. Overall, Merck KGaA has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's EPS (Basic) compare to ZTS and UTHR?
Merck KGaA's EPS (Basic) of €5.83 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Merck KGaA and its competitors. Merck KGaA's current EPS (Basic) is €5.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Based on GuruFocus' analysis, Merck KGaA (CHIX:MRKD) is currently considered Fairly Valued. The stock's GF Value™ is €140.71, compared to a current price of €128.75 — trading 8.5% below its estimated fair value. The current EPS (Basic) is €5.83. Merck KGaA's overall GF Score™ is 83/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Merck KGaA (CHIX:MRKD), the current EPS (Basic) is €5.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (CHIX:MRKD) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be undervalued. The current stock price of €128.75 is trading 8.5% below its estimated GF Value™ of €140.71. GuruFocus considers Merck KGaA to be Fairly Valued.

Key valuation signals for CHIX:MRKD:

  • EPS (Basic): €5.83
  • GF Value™: €140.71 vs. price of €128.75 (8.5% below fair value)
  • GF Score™: 83/100 with 9 warning signs

No single metric tells the full story. See the CHIX:MRKD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
83GF Score

Get the complete analysis for CHIX:MRKD

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€128.75
Price
€140.71
GF Value